Akari Therapeutics (AKTX) Competitors $1.11 +0.02 (+1.85%) Closing price 03:51 PM EasternExtended Trading$1.11 +0.00 (+0.36%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock AKTX vs. VTYX, LXEO, THTX, BDTX, ALTS, LYEL, IKT, SKYE, GALT, and GLSIShould you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Ventyx Biosciences (VTYX), Lexeo Therapeutics (LXEO), Theratechnologies (THTX), Black Diamond Therapeutics (BDTX), ALT5 Sigma (ALTS), Lyell Immunopharma (LYEL), Inhibikase Therapeutics (IKT), Skye Bioscience (SKYE), Galectin Therapeutics (GALT), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical products" industry. Akari Therapeutics vs. Its Competitors Ventyx Biosciences Lexeo Therapeutics Theratechnologies Black Diamond Therapeutics ALT5 Sigma Lyell Immunopharma Inhibikase Therapeutics Skye Bioscience Galectin Therapeutics Greenwich LifeSciences Ventyx Biosciences (NASDAQ:VTYX) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership. Does the media favor VTYX or AKTX? In the previous week, Akari Therapeutics had 1 more articles in the media than Ventyx Biosciences. MarketBeat recorded 3 mentions for Akari Therapeutics and 2 mentions for Ventyx Biosciences. Ventyx Biosciences' average media sentiment score of 1.30 beat Akari Therapeutics' score of 0.49 indicating that Ventyx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ventyx Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akari Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend VTYX or AKTX? Ventyx Biosciences currently has a consensus target price of $10.00, suggesting a potential upside of 219.49%. Given Ventyx Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Ventyx Biosciences is more favorable than Akari Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ventyx Biosciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is VTYX or AKTX more profitable? Ventyx Biosciences' return on equity of -47.45% beat Akari Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ventyx BiosciencesN/A -47.45% -43.49% Akari Therapeutics N/A -213.59%-65.60% Do institutionals and insiders hold more shares of VTYX or AKTX? 97.9% of Ventyx Biosciences shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 14.5% of Ventyx Biosciences shares are held by company insiders. Comparatively, 38.1% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, VTYX or AKTX? Ventyx Biosciences has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Which has preferable earnings & valuation, VTYX or AKTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVentyx BiosciencesN/AN/A-$135.12M-$1.75-1.79Akari TherapeuticsN/AN/A-$19.79MN/AN/A SummaryVentyx Biosciences beats Akari Therapeutics on 8 of the 11 factors compared between the two stocks. Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKTX vs. The Competition Export to ExcelMetricAkari TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.07M$2.91B$5.52B$9.32BDividend YieldN/A2.46%4.25%4.05%P/E RatioN/A20.3628.1519.68Price / SalesN/A302.56437.63100.28Price / CashN/A42.3835.5357.53Price / Book1.327.768.235.67Net Income-$19.79M-$55.11M$3.23B$257.51M7 Day Performance-1.46%0.95%-0.01%0.52%1 Month Performance1.83%8.44%5.61%8.84%1 Year Performance-70.00%-2.38%26.52%14.18% Akari Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKTXAkari Therapeutics0.8749 of 5 stars$1.11+1.9%N/A-70.9%$35.07MN/A0.009News CoverageVTYXVentyx Biosciences3.4748 of 5 stars$2.04-1.9%$10.00+390.2%+6.7%$148.01MN/A-1.1730Positive NewsLXEOLexeo Therapeutics2.0172 of 5 stars$4.54+2.0%$16.60+265.6%-68.3%$147.73M$650K-1.3858Gap UpHigh Trading VolumeTHTXTheratechnologiesN/A$3.17-0.9%N/A+103.9%$147.14M$85.87M-39.63140Earnings ReportHigh Trading VolumeBDTXBlack Diamond Therapeutics2.8633 of 5 stars$2.50-3.1%$12.80+412.0%-51.0%$146.71MN/A41.6790News CoveragePositive NewsALTSALT5 Sigma0.1376 of 5 stars$7.54-8.4%N/AN/A$143.65M$12.53M0.00170LYELLyell Immunopharma3.2442 of 5 stars$9.15-5.6%$15.00+63.9%-73.5%$143.49M$60K-0.37270News CoverageIKTInhibikase Therapeutics1.1922 of 5 stars$1.93+2.1%$6.50+236.8%+20.8%$143.48MN/A-0.726SKYESkye Bioscience2.1421 of 5 stars$4.39-4.8%$16.60+278.1%-40.6%$142.80MN/A-5.3511GALTGalectin Therapeutics2.2552 of 5 stars$2.15-1.4%$6.00+179.1%+17.6%$137.98MN/A-2.999GLSIGreenwich LifeSciences2.1453 of 5 stars$10.07+0.4%$39.00+287.3%-35.6%$134.08MN/A-7.993 Related Companies and Tools Related Companies Ventyx Biosciences Competitors Lexeo Therapeutics Competitors Theratechnologies Competitors Black Diamond Therapeutics Competitors ALT5 Sigma Competitors Lyell Immunopharma Competitors Inhibikase Therapeutics Competitors Skye Bioscience Competitors Galectin Therapeutics Competitors Greenwich LifeSciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKTX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredFirst time revealing what I do with my own moneyMy mom has made 3,400% returns - here’s her 3-Stock Secret' Joel Litman is an accountant. So is his mom, wh...Altimetry | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKTX Stock Alerts